Cancer stem cell inhibitor
The object of the present invention is to provide a novel pharmaceutical for suppressing cancer stem cells. In the present invention, a mitochondria inhibitor comprising a 2-nitroimidazole derivative is applied to the cancer stem cell as an active ingredient.
1. A method for suppressing a cancer stem cell, the method comprising:
contacting the cancer stem cell with a pharmaceutical comprising a 2-nitroimidazole derivative as an active ingredient,
wherein the cancer stem cell is glioma, melanoma, or sarcoma, and
wherein the 2-nitroimidazole derivative is doranidazole, misonidazole, or etanidazole.
2. The method according to claim 1 , wherein the cancer stem cell is derived from metastatic cancer.
3. The method according to claim 1 , wherein the pharmaceutical is contacted together with a cancer damaging means.
4. The method according to claim 3 , wherein the cancer damaging means is administration of a cancer chemotherapeutic agent or radiation.
5. The method according to claim 3 , wherein the pharmaceutical is suitable for pretreatment, concurrent treatment, or posttreatment of the cancer damaging means.
6. A method for suppressing growth of a cancer stem cell, the method comprising:
administering a 2-nitroimidazole derivative to a subject in need thereof,
wherein the cancer stem cell is glioma, melanoma, or sarcoma, and
wherein the 2-nitroimidazole derivative is doranidazole, misonidazole, or etanidazole.